-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Agios Pharma (AGIO)
-
-
-
-
-
-
-
RBC Capital Downgrades Agios Pharma (AGIO) to Sector Perform
-
-
-
-
-
-
-
TD Cowen on Agios Pharma (AGIO): 'we view an extension rather than issuance of a CRL as a positive sign'
-
-
-
-
-
-
-
Agios Reports Second Quarter 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
RBC Capital Explores Biotech Implications Following Cavazzoni's Departure from the FDA
-
-
-
-
-
-
-
Royalty Pharma plc (RPRX) and Agios Pharmaceuticals (AGIO) Enter Into Vorasidenib Royalty Agreement for $905 Million
-
-
-
-
-
-
-
Agios Pharma (AGIO) Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency
-
15,579 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

